ArticleInfection and immunity2008
Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- High sensitive detection of carbohydrate binding proteins in an ELISA-solid phase assay based on multivalent glyconanoparticles.PloS one · 2013Trial
- Synthetic Access to Fluorinated Analogs of a KnownACS organic & inorganic Au · 2026Article
- Antigen-driven Convergent Evolution of Polysaccharide-specific "DH-less" B Cells in Glycoconjugate Immunized Mice.ImmunoHorizons · 2024Article
- A Multidisciplinary Structural Approach to the Identification of theACS central science · 2024Article
- Semisynthetic Pneumococcal Glycoconjugate Nanovaccine.Bioconjugate chemistry · 2023Article
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Impact and Control of Sugar Size in Glycoconjugate Vaccines.Molecules (Basel, Switzerland) · 2022Review
- Total synthesis ofChemical science · 2022Article
- Glycan Microarrays Containing Synthetic Streptococcus pneumoniae CPS Fragments and Their Application to Vaccine Development.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines.NPJ vaccines · 2021Review
- On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.Glycoconjugate journal · 2021Article
- Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.Chemical reviews · 2021Review
- Synthetic Analogs ofRussian journal of bioorganic chemistry · 2021Article
- Chimeric oligosaccharide conjugate induces opsonic antibodies againstChemical science · 2020Article
- Automated glycan assembly ofRSC advances · 2020Article
- Selectively Charged and Zwitterionic Analogues of the Smallest Immunogenic Structure of Streptococcus Pneumoniae Type 14.Molecules (Basel, Switzerland) · 2019Article
- Conformation and Cross-Protection in Group B Streptococcus Serotype III andPharmaceuticals (Basel, Switzerland) · 2019Article
- Site-Specific Conjugation for Fully Controlled Glycoconjugate Vaccine Preparation.Frontiers in chemistry · 2019Article
- Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development.Molecules (Basel, Switzerland) · 2018Review
- Semisynthetic glycoconjugate vaccine candidate againstProceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic overlapping oligosaccharide fragments of Streptococcus pneumoniae serotype 14 capsular polysaccharide (Pn14PS), [6)-[beta-D-Galp-(1-->4)-]beta-D-GlcpNAc-(1-->3)-beta-D-Galp-(1-->4)-beta-D-Glcp-(1-->](n), were conjugated to CRM(197) protein and injected into mice to determine the smallest immunogenic structure. The resulting antibodies were then tested for Pn14PS specificity and for their capacity to promote the phagocytosis of S. pneumoniae type 14 bacteria. Earlier studies have reported that the oligosaccharide corresponding to one structural repeating unit of Pn14PS, i.e., Gal-Glc-(Gal-)GlcNAc, induces a specific antibody response to Pn14PS. The broader study described here, which evaluated 16 oligosaccharides, showed that the branched trisaccharide element Glc-(Gal-)GlcNAc is essential in inducing Pn14PS-specific antibodies and that the neighboring galactose unit at the nonreducing end contributes clearly to the immunogenicity of the epitope. Only the oligosaccharide conjugates that produce antibodies recognizing Pn14PS were capable of promoting the phagocytosis of S. pneumoniae type 14. In conclusion, the branched tetrasaccharide Gal-Glc-(Gal-)GlcNAc may be a serious candidate for a synthetic oligosaccharide conjugate vaccine against infections caused by S. pneumoniae type 14.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.